Supernus Pharmaceuticals SUPN Income Statement
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| $207.71M+38.6% | $211.57M+21.5% | $192.1M+9.3% | $165.45M-1.7% | $149.82M+4.3% | ||
| $23.39M+48.4% | $23.01M-11.8% | $18.97M+7.9% | $16.83M-6.1% | $15.76M-3.3% | ||
| $184.31M+37.5% | $188.57M+27.4% | $173.14M+9.5% | $148.63M-1.2% | $134.06M+5.3% | ||
| 88.7%-0.7pp | 89.1%+4.1pp | 90.1%+0.1pp | 89.8%+0.5pp | 89.5%+0.8pp | ||
| $39.44M+46.5% | $27.83M-2.9% | $29.37M+1.1% | $22.12M-15.5% | $26.93M+8.0% | ||
| $125.17M+39.2% | $122.39M+54.1% | $179.68M+158% | $93.55M+8.9% | $89.94M+4.0% | ||
| $216.04M+35.0% | $215.51M+41.1% | $252.33M+87.1% | $153.31M+5.2% | $160.08M+9.0% | ||
| -$8.33M+18.8% | -$3.94M-118% | -$60.23M-247% | $12.14M-46.2% | -$10.26M-225% | ||
| -4%+2.8pp | -1.9%-14.2pp | -31.4%-54.6pp | 7.3%-6.1pp | -6.8%-4.7pp | ||
| $2.38M-46.2% | $2.02M-59.4% | $2.28M-44.4% | $4.53M+21.3% | $4.43M+30.3% | ||
| -$5.95M-2.0% | -$1.91M-107% | -$57.95M-229% | $16.67M-36.6% | -$5.83M-2,500% | ||
| -$3.66M-161% | —— | -$12.84M-299% | -$5.83M-191% | $6M+4,939% | ||
| -$2.29M+80.6% | -$4.11M-127% | -$45.12M-217% | $22.5M+13.0% | -$11.83M-9,638% | ||
| -1.1%+6.8pp | -1.9%-10.7pp | -23.5%-45.4pp | 13.6%+1.8pp | -7.9%-8.0pp | ||
| -$0.04+81.0% | -$0.07-126% | -$0.80-216% | $0.40+11.1% | -$0.21— | ||
| $17.8M+75.8% | $21.08M-47.6% | -$35.43M-158% | $33.5M-22.6% | $10.13M-42.4% | ||
| 8.6%+1.8pp | 10%-13.1pp | -18.4%-53.1pp | 20.2%-5.5pp | 6.8%-5.5pp | ||
| -$8.33M+18.8% | -$3.94M-118% | -$60.23M-247% | $12.14M-46.2% | -$10.26M-225% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What is Supernus Pharmaceuticals's revenue?
- Supernus Pharmaceuticals (SUPN) generated $776.8M in revenue over the trailing twelve months, up 16.3% year over year.
- Is Supernus Pharmaceuticals profitable?
- Supernus Pharmaceuticals is not currently profitable: it reported a net loss of $29.0M over the trailing twelve months, a -3.7% net margin.
- What are Supernus Pharmaceuticals's profit margins?
- Gross margin is 89.4% and operating margin is -7.8%, with a -3.7% net margin.
- What is Supernus Pharmaceuticals's earnings per share?
- Supernus Pharmaceuticals's diluted EPS over the trailing twelve months is $-0.51.
- Where does Supernus Pharmaceuticals's income statement data come from?
- Every line is extracted from Supernus Pharmaceuticals's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
